product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
CD229/SLAMF3/Lymphocyte Antigen 9 Antibody (017) [DyLight 550]
catalog :
NBP2-90618R
quantity :
0.1 ml
price :
539 USD
clonality :
monoclonal
host :
domestic rabbit
conjugate :
DyLight 550
clone name :
017
reactivity :
human, mouse
application :
ELISA
more info or order :
product information
brand :
Novus
master code :
NBP2-90618R
SKU :
NBP2-90618R
product name :
CD229/SLAMF3/Lymphocyte Antigen 9 Antibody (017) [DyLight 550]
sizes available :
0.1 ml
description :
The CD229/SLAMF3/Lymphocyte Antigen 9 Antibody (017) [DyLight 550] from NBP2-90618R is a 6.7e-05 antibody to . This antibody reacts with mouse.
target :
CD229/SLAMF3/Lymphocyte Antigen 9
category :
Primary Antibodies
buffer :
50mM Sodium Borate
clonality :
Monoclonal
clone :
017
conjugate :
DyLight 550
all_available conjugate :
Biotin;DyLight 550
dilution :
ELISA
host :
Rabbit
immunogen :
This antibody was obtained from a rabbit immunized with purified, recombinant Mouse CD229/SLAMF3/Lymphocyte Antigen 9 (Accession#: NP_032560.2; Met 1-Arg 453).
isotype :
IgG
purity :
Protein A purified
species :
Mouse
gene symbol :
LY9
applications :
ELISA
extended description :
Recombinant Monoclonal Antibody
USD :
539 USD
product details :
Recombinant Monoclonal Antibody
alt names :
CD229, CD229 antigen, cell-surface molecule Ly-9, hly9, lymphocyte antigen 9Cell surface molecule Ly-9, mLY9, SLAMF3, T-lymphocyte surface antigen Ly-9
storage :
Store at 4C in the dark.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
browse more products
questions and comments
